Combined Inhibition of MEK and Plk1 Has Synergistic Antitumor Activity in NRAS Mutant Melanoma

Journal of Investigative Dermatology

Volumn 135, Issue 10, 2015, Pages 2475-2483

  Posch, Christian ^a,b,c   Cholewa, Brian D ^d   Vujic, Igor ^a,c   Sanlorenzo, Martina ^a,e   Ma, Jeffrey ^a   Kim, Sarasa T ^a   Kleffel, Sonja ^b   Schatton, Tobias ^b   Rappersberger, Klemens ^c   Gutteridge, Rosie ^d   Ahmad, Nihal ^d   Ortiz Urda, Susana ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Universitatsklinik fur Dermatologie   (Austria)

^d University of Wisconsin Health   (United States)

^e UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BIM PROTEIN; CASPASE 3; CASPASE 7; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; POLO LIKE KINASE 1; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; TRAMETINIB; VOLASERTIB; CELL CYCLE PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER REGRESSION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MELANOMA CELL LINE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; ONCOGENE N RAS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE CHECKPOINT; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; ONCOGENE RAS; PATHOLOGY; RANDOMIZATION; RAT; SKIN TUMOR; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL CYCLE CHECKPOINTS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; GENES, RAS; HETEROGRAFTS; HUMANS; MAP KINASE KINASE 1; MELANOMA; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; RANDOM ALLOCATION; RATS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS;

EID: 84941415189     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2015.198     Document Type: Article

References (57)

1. Anderson VE, Walton MI, Eve PD et al. (2011) CCT241533 is a potent and selective inhibitor of CHK2 that potentiates the cytotoxicity of PARP inhibitors. Cancer Res 71: 463-72
2. Ando K, Ozaki T, Yamamoto H et al. (2004) Polo-like kinase 1 (Plk1) inhibits p53 function by physical interaction and phosphorylation. J Biol Chem 279: 25549-61
3. Ascierto PA, Schadendorf D, Berking C et al. (2013) MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncol 14: 249-56
4. Atefi M, von Euw E, Attar N et al. (2011) Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One 6: e28973
5. Atefi M, Titz B, Avramis E et al. (2015) Combination of Pan-RAF and MEK inhibitors in NRAS mutant melanoma. Mol Cancer 14: 27
6. Balamurugan K, Sterneck E (2013) The many faces of C/EBP and their relevance for inflammation and cancer. Int J Biol Sci 9: 917-33
7. Beria I, Ballinari D, Bertrand JA et al. (2010) Identification of 4, 5-dihydro-1Hpyrazolo[ 4, 3-h]quinazoline derivatives as a new class of orally and selective Polo-like kinase 1 inhibitors. J Med Chem 53: 3532-51
8. Bos JL (1989) Ras oncogenes in human cancer: a review. Cancer Res 49: 4682-9
9. Burd CE, Liu W, Huynh MV et al. (2014) Mutation-specific RAS oncogenicity explains NRAS codon 61 selection in melanoma. Cancer Discov 4: 1418-29
10. Catalanotti F, Solit DB, Pulitzer MP et al. (2013) Phase II trial of MEK inhibitor selumetinib (AZD6244, ARRY-142886) in patients with BRAFV600E/Kmutated melanoma. Clin Cancer Res Off J Am Assoc Cancer Res 19: 2257-64
11. Cerami E, Gao J, Dogrusoz U et al. (2012) The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2: 401-4
12. Cholewa BD, Liu X, Ahmad N (2013) The role of polo-like kinase 1 in carcinogenesis: cause or consequence? Cancer Res 73: 6848-55
13. Cholewa BD, Pellitteri-Hahn MC, Scarlett CO et al. (2014) Large-scale label-free comparative proteomics analysis of Polo-like kinase 1 inhibition via the small-molecule inhibitor BI 6727 (Volasertib) in BRAF(V600E) mutant melanoma cells. J Proteome Res 13: 5041-50
14. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55
15. Dong J (2013) Overcoming resistance to BRAF and MEK inhibitors by simultaneous suppression of CDK4. In: Duc H (ed) Melanoma-Early Detect. Treat. InTech
16. Eskandarpour M, Kiaii S, Zhu C et al. (2005) Suppression of oncogenic NRAS by RNA interference induces apoptosis of human melanoma cells. Int J Cancer J Int Cancer 115: 65-73
17. FedorenkoIV, Gibney GT, Smalley KSM (2013) NRAS mutant melanoma: biological behavior and future strategies for therapeutic management. Oncogene 32: 3009-18
18. Gao J, Aksoy BA, Dogrusoz U et al. (2013) Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 6: pl1
19. Gray PJ, Bearss DJ, Han H et al. (2004) Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol Cancer Ther 3: 641-6
20. Greger JG, Eastman SD, Zhang V et al. (2012) Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 11: 909-20
21. Gumireddy K, Reddy MVR, Cosenza SC et al. (2005) ON01910, a non-ATPcompetitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7: 275-86
22. Jaiswal BS, Janakiraman V, Kljavin NM et al. (2009) Combined targeting of BRAF and CRAF or BRAF and PI3K effector pathways is required for efficacy in NRAS mutant tumors. PLoS One 4: e5717
23. Jakob JA, Bassett RL Jr, Ng CS et al. (2012) NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer 118: 4014-23
24. Jalili A, Moser A, Pashenkov M et al. (2011) Polo-like kinase 1 is a potential therapeutic target in human melanoma. J Invest Dermatol 131: 1886-95
25. Jiang H, Reinhardt HC, Bartkova J et al. (2009) The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 23: 1895-909
26. Kelleher FC, McArthur GA (2012) Targeting NRAS in melanoma. Cancer J Sudbury Mass 18: 132-6
27. Knecht R, Elez R, Oechler M et al. (1999) Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res 59: 2794-7
28. Komatsu S, Takenobu H, Ozaki T et al. (2009) Plk1 regulates liver tumor cell death by phosphorylation of TAp63. Oncogene 28: 3631-41
29. Kreis N-N, Sommer K, Sanhaji M et al. (2009) Long-term downregulation of Polo-like kinase 1 increases the cyclin-dependent kinase inhibitor p21 (WAF1/CIP1). Cell Cycle Georget Tex 8: 460-72
30. Kwong LN, Costello JC, Liu H et al. (2012) Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma. Nat Med 18: 1503-10
31. Lane HA, Nigg EA (1996) Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes. J Cell Biol 135: 1701-13
32. Lansing TJ, McConnell RT, Duckett DR et al. (2007) In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther 6: 450-9
33. Lin C-C, Su W-C, Yen C-J et al. (2014) A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer 110: 2434-40
34. Liu X, Lei M, Erikson RL (2006) Normal cells, but not cancer cells, survive severe Plk1 depletion. Mol Cell Biol 26: 2093-108
35. Long GV, Fung C, Menzies AM et al. (2014) Increased MAPK reactivation in early resistance to dabrafenib/trametinib combination therapy of BRAFmutant metastatic melanoma. Nat Commun 5: 5694
36. Luo J, Emanuele MJ, Li D et al. (2009) A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell 137: 835-48
37. Mishra PJ, Ha L, Rieker J et al. (2010) Dissection of RAS downstream pathways in melanomagenesis: a role for Ral in transformation. Oncogene 29: 2449-56
38. Modi PK, Komaravelli N, Singh N et al. (2012) Interplay between MEK-ERK signaling, cyclin D1, and cyclin-dependent kinase 5 regulates cell cycle reentry and apoptosis of neurons. Mol Biol Cell 23: 3722-30
39. Omerovic J, Laude AJ, Prior IA (2007) Ras proteins: paradigms for compartmentalised and isoform-specific signalling. Cell Mol Life Sci 64: 2575-89
40. Posch C, Moslehi H, Feeney L et al. (2013) Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci USA 110: 4015-20
41. Rebecca VW, Alicea GM, Paraiso KHT et al. (2014) Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma. Pigment Cell Melanoma Res 27: 1154-8
42. Repasky GA, Chenette EJ, Der CJ (2004) Renewing the conspiracy theory debate: does Raf function alone to mediate Ras oncogenesis? Trends Cell Biol 14: 639-47
43. Rudolph D, Steegmaier M, Hoffmann M et al. (2009) BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res 15: 3094-102
44. Schmit TL, Zhong W, Setaluri V et al. (2009) Targeted depletion of Polo-like kinase (Plk) 1 through lentiviral shRNA or a small-molecule inhibitor causes mitotic catastrophe and induction of apoptosis in human melanoma cells. J Invest Dermatol 129: 2843-53
45. Schubbert S, Shannon K, Bollag G (2007) Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 7: 295-308
46. Seong Y-S, Kamijo K, Lee J-S et al. (2002) A spindle checkpoint arrest and a cytokinesis failure by the dominant-negative polo-box domain of Plk1 in U-2 OS cells. J Biol Chem 277: 32282-93
47. Stadler WM, Vaughn DJ, Sonpavde G et al. (2014) An open-label, single-arm, phase 2 trial of the Polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer 120: 976-82
48. Steegmaier M, Hoffmann M, Baum A et al. (2007) BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17: 316-22
49. Strebhardt K (2010) Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov 9: 643-60
50. Sumara I, Giménez-Abián JF, Gerlich D et al. (2004) Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol 14: 1712-22
51. Tsvetkov L, Xu X, Li J et al. (2003) Polo-like kinase 1 and Chk2 interact and colocalize to centrosomes and the midbody. J Biol Chem 278: 8468-75
52. Van Vugt MATM, van de Weerdt BCM, Vader G et al. (2004) Polo-like kinase-1 is required for bipolar spindle formation but is dispensable for anaphase promoting complex/Cdc20 activation and initiation of cytokinesis. J Biol Chem 279: 36841-54
53. Vujic I, Posch C, Sanlorenzo M et al. (2014) Mutant NRAS Q61 shares signaling similarities across various cancer types-potential implications for future therapies. Oncotarget 5: 7936-44
54. Wang Y, Kaiser CE, Frett B et al. (2013) Targeting mutant KRAS for anticancer therapeutics: a review of novel small molecule modulators. J Med Chem 56: 5219-30
55. Wolf G, Elez R, Doermer A et al. (1997) Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 14: 543-9
56. Yim H, Erikson RL (2014) Plk1-targeted therapies in TP53-or RASmutated cancer. Mutat Res Rev Mutat Res pii: S1383-5742(14)00019-2. doi: 10. 1016/j. mrrev. 2014. 02. 005. [Epub ahead of print]
57. Yoo HY, Kumagai A, Shevchenko A et al. (2004) Adaptation of a DNA replication checkpoint response depends upon inactivation of Claspin by the Polo-like kinase. Cell 117: 575-88